quinoxalines has been researched along with glutathione disulfide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheung, PY; Schulz, R | 1 |
| Guo, Y; Regan, RF | 1 |
2 other study(ies) available for quinoxalines and glutathione disulfide
| Article | Year |
|---|---|
Glutathione causes coronary vasodilation via a nitric oxide- and soluble guanylate cyclase-dependent mechanism.
Topics: Analysis of Variance; Animals; Blood Pressure; Carmustine; Coronary Circulation; Coronary Vessels; Enzyme Inhibitors; Glutathione; Glutathione Disulfide; Glyburide; Guanylate Cyclase; Heart; Heart Rate; In Vitro Techniques; Indomethacin; Male; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Oxadiazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Superoxide Dismutase; Vasodilation; Ventricular Function, Left | 1997 |
Extracellular reduced glutathione increases neuronal vulnerability to combined chemical hypoxia and glucose deprivation.
Topics: Animals; Cells, Cultured; Dizocilpine Maleate; Edetic Acid; Excitatory Amino Acid Antagonists; Glucose; Glutathione; Glutathione Disulfide; Hypoxia, Brain; Mercaptoethanol; Mice; Neurons; Oxidation-Reduction; Quinoxalines; Synaptic Transmission | 1999 |